Local Lymph Node Assay (LLNA) for Cosmetics: Principles, Methods, and Regulatory Applications

The Local Lymph Node Assay (LLNA) is a internationally recognized method for evaluating the skin sensitization potential of cosmetic ingredients and finished products. Based on OECD Test Guideline 429 and its non-radioactive variants, the assay quantifies lymphocyte proliferation in draining auricular lymph nodes to classify substances as sensitizers and estimate their potency. This article explains the technical principles, sample types, testing procedures, regulatory applications, and common questions related to LLNA testing for cosmetics.

Technical Overview

The Local Lymph Node Assay (LLNA) is an in vivo toxicological test designed to identify the skin sensitization hazard of chemicals, including cosmetic raw materials and finished formulations. Skin sensitization, also known as allergic contact dermatitis, is an immunologically mediated adverse reaction that occurs when a susceptible individual is re-exposed to a sensitizing substance. The LLNA identifies the induction phase of this process by measuring the proliferative response of T lymphocytes in the lymph nodes that drain the site of topical exposure.

Compared with traditional guinea pig methods such as the Magnusson-Kligman maximization test and the Buehler assay, the LLNA offers several important advantages:

• Fewer animals are required, and the procedure causes less pain and distress, aligning with the 3Rs principle (replacement, reduction, and refinement).
• The endpoint is quantitative and objective, based on measured cellular proliferation rather than subjective visual scoring of erythema.
• The assay generates dose-response information, enabling potency estimation for risk assessment.
• Test substances are applied topically, which mirrors the realistic route of consumer exposure to cosmetics.

The core metric of the assay is the Stimulation Index (SI), calculated as the ratio of lymph node response in treated animals to that in vehicle controls. An SI value of 3.0 or greater, supported by statistical analysis and a dose-response relationship, classifies the substance as a skin sensitizer. The assay is harmonized under OECD Test Guideline 429 (radiolabeled version), OECD Test Guideline 442A (LLNA: DA based on ATP measurement), and OECD Test Guideline 442B (LLNA: BrdU-ELISA). In China, the method is included in the national Safety and Technical Standards for Cosmetics and is a key data requirement for new cosmetic ingredient registration and filing dossiers.

Testing Samples

Cosmetic Raw Materials and New Ingredients

Individual ingredients represent the primary category of samples evaluated by the LLNA. These include preservatives, ultraviolet filters, fragrance compounds, surfactants, colorants, film formers, antioxidants, and botanical extracts. For new cosmetic ingredients undergoing registration or notification, skin sensitization data are generally mandatory, and the LLNA remains a scientifically accepted study type where existing alternative data are insufficient or where regulations explicitly permit in vivo testing.

Finished Cosmetic Products

Finished formulations, including leave-on products such as creams, lotions, sunscreens, and makeup, as well as rinse-off products such as shampoos and cleansers, may be tested when ingredient-based assessment cannot resolve the sensitization profile of the complete formula. Sample preparation must account for the solubility, pH, viscosity, and irritancy potential of the product matrix to avoid false results.

Extracts and Impurities

Leachables and extracts from packaging materials, reaction by-products, degradation products, and process-related impurities may also be assessed, particularly when a safety concern has been identified during the risk assessment of the product lifecycle.

Testing Items

A standard LLNA study delivers the following testing items and outcomes:

• Skin sensitization hazard identification: classification of the test substance as a sensitizer or non-sensitizer based on the SI threshold of 3.0.
• Stimulation Index (SI): quantitative proliferation values for each dose group compared with the vehicle control.
• EC3 value: the estimated concentration of the test substance required to produce a threefold increase in lymph node cell proliferation, derived by interpolation from the dose-response curve.
• Potency categorization: classification into extreme, strong, moderate, or weak potency bands (for example, EC3 values at or below 0.2 percent indicate extreme potency, while values between 2 and 20 percent indicate moderate potency), supporting hazard subcategorization under the UN GHS framework.
• Local irritation assessment: ear thickness measurements and clinical observations to distinguish genuine sensitization responses from irritation-driven inflammation.
• Dose-response characterization: slope and monotonicity analysis supporting the biological plausibility of the result.

Testing Methods

Standard Radiolabeled LLNA (OECD TG 429)

In the reference method, young adult female mice of an appropriate strain such as CBA are assigned to a vehicle control group, treatment groups, and often a positive control group. The test substance is applied to the dorsal surface of both ears once daily for three consecutive days. After a rest period, the draining auricular lymph nodes are excised, and single-cell suspensions are prepared. Lymphocyte proliferation is quantified by measuring the incorporation of radiolabeled thymidine into newly synthesized DNA, expressed as disintegrations per minute per lymph node. The SI is then calculated for each dose group.

Non-Radioactive Variants (OECD TG 442A and 442B)

To accommodate laboratories that cannot handle radioisotopes, two validated variants are widely used. The LLNA: DA method (OECD TG 442A) measures intracellular adenosine triphosphate as a marker of cell proliferation using a bioluminescent assay. The LLNA: BrdU-ELISA method (OECD TG 442B) measures the incorporation of bromodeoxyuridine, a thymidine analog, detected by enzyme-linked immunosorbent assay. Both variants follow the same exposure regimen and use the same SI decision threshold as the reference method.

Study Design, Controls, and Interpretation

Vehicle selection is critical; acetone and olive oil in a 4:1 ratio, dimethylformamide, methyl ethyl ketone, and propylene glycol are commonly used, and the vehicle must dissolve or uniformly suspend the test substance without causing irritation. Dose levels are selected based on a preliminary irritation and systemic toxicity screen, with a maximum concentration of 100 percent for liquids and the highest practically applicable concentration for solids. A concurrent positive control, such as 25 percent hexyl cinnamic aldehyde, verifies assay sensitivity, while historical control data confirm laboratory proficiency.

Results are interpreted with caution: an SI of 3.0 or greater with a dose-response indicates a sensitizer, while excessive local irritation, indicated by marked ear swelling, may confound the result and lead to false positives. A reduced protocol using a single high dose plus controls (rLLNA) may be applied when only hazard identification, not potency, is required. Where animal testing is restricted, such as for cosmetics marketed in regions with testing bans, the LLNA is complemented or replaced by in vitro and in chemico methods, including the DPRA, KeratinoSens, and h-CLAT assays, and by defined approaches combining multiple non-animal data sources under OECD guidance.

Applications

The LLNA supports a broad range of regulatory and commercial applications in the cosmetics sector and adjacent industries:

• New cosmetic ingredient dossiers: generating sensitization endpoints required for ingredient registration, notification, and safety assessment under national cosmetic regulations.
• Product safety evaluation: verifying the overall sensitization risk of finished formulations before market launch, particularly for leave-on products with prolonged skin contact.
• Hazard classification and labeling: assigning skin sensitization categories under the UN GHS and related regional classification frameworks.
• Exposure limits and safe use levels: using EC3-derived potency data to set maximum safe concentrations of ingredients, for example in fragrance risk assessment programs.
• Medical device biocompatibility: the LLNA is also accepted under ISO 10993-10 as a sensitization test for device materials and extracts, which is relevant for cosmetic applicators and dermal devices.
• Weight-of-evidence assessments: integrating LLNA results with in silico predictions, chemistry-based assays, and clinical or epidemiological data to reach an overall safety conclusion.

FAQ

What is the difference between the LLNA and guinea pig sensitization tests?

Guinea pig methods assess elicitation reactions by visually scoring skin erythema after induced and challenge exposures. The LLNA instead measures the induction phase quantitatively by counting lymphocyte proliferation in draining lymph nodes. It requires fewer animals, avoids adjuvant injection, produces objective numerical data, and provides potency information that guinea pig tests cannot.

What does an EC3 value mean?

The EC3 value is the effective concentration of a test substance estimated to triple lymph node proliferation compared with the vehicle control. Lower EC3 values indicate stronger sensitizers. This value allows substances to be ranked by potency and supports the derivation of safe exposure thresholds in cosmetic risk assessment.

Can the LLNA produce false results?

Yes. Strong irritants can cause inflammation-driven lymph node proliferation and false positives, which is why ear irritation is monitored throughout the study. Conversely, certain metal salts and highly lipophilic or poorly bioavailable substances may yield false negatives. Careful vehicle selection, dose-limiting based on irritation screening, and expert interpretation mitigate these risks.

Is the LLNA still accepted given animal testing bans on cosmetics?

Acceptance depends on the regulatory framework of the target market. In jurisdictions where animal testing for cosmetics is prohibited, validated non-animal methods and defined approaches are used instead. In other markets, including certain new ingredient registration pathways in China, the LLNA remains a recognized study type under the national Safety and Technical Standards for Cosmetics when no adequate alternative data exist.

Why choose a non-radioactive LLNA variant?

The LLNA: DA and LLNA: BrdU-ELISA variants eliminate the need for radioisotope facilities while maintaining validated performance comparable to the reference method. They are practical options for laboratories seeking to reduce radiological waste and simplify logistics without compromising regulatory acceptance.